Cost variation analysis of commonly used oral antidiabetic drugs available in the Indian pharmaceutical market: a cross-sectional study

Sathiyanathan T.; Rie Joshi; Shailander Singh; Preeti Dharapur; Steffi Loarine

doi:10.18203/2319-2003.ijbcp20252575

Authors

Sathiyanathan T. Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar, Affiliated to RGUHS Bengaluru, Karnataka, India
Rie Joshi Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar, Affiliated to RGUHS Bengaluru, Karnataka, India
Shailander Singh Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar, Affiliated to RGUHS Bengaluru, Karnataka, India
Preeti Dharapur Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar, Affiliated to RGUHS Bengaluru, Karnataka, India
Steffi Loarine Department of Forensic medicine, Bidar Institute of Medical Sciences, Bidar, Affiliated to RGUHS Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20252575

Keywords:

Drug costs, Government regulation, Hypoglycaemic agents pharmacoeconomics

Abstract

Background: Type 2 diabetes mellitus (DM) is a chronic, progressive metabolic disease that can lead to both microvascular and macrovascular problems. OHAs, or oral hypoglycemic agents, are crucial for controlling elevated blood glucose levels and treatment adherence. The cost of medications affects both patient adherence and sensible prescribing. In India, the same antidiabetic drugs are sold under several different brands at wildly disparate costs. Financial burden may result from prescribing pricey brands, particularly for long-term illnesses like diabetes mellitus. Aim was to enumerate the price of commonly used oral antidiabetic drugs in India and study the cost variation of oral antidiabetic drugs.

Methods: Data from CIMS April-June 2024 on 17 antidiabetic drugs (various strengths) were analysed. Maximum and minimum prices (per 10 tablets) were recorded. Cost differences, cost ratios, and cost variation percentages were calculated using MS Excel 2021, with data represented in tables and charts.

Results: Overall, the maximum and minimum cost variation among individual drugs were linagliptin 5 mg (586.67%) and glibenclamide 5 mg (39.80%) respectively. Among FDC’s the minimum cost variation was glibenclamide + metformin (5+500 mg SR tablet; 4.77%) and maximum cost variation was of glimepiride + metformin (1+500 mg SR tablet; 1246.47%).

Conclusions: The prices of the numerous brands of oral anti-diabetics that are sold in the Indian market vary greatly. Physicians need to be aware of these differences and prescribe medications appropriately, taking the patient’s financial situation into account and also to encourage treatment compliance.

Metrics

Metrics Loading ...

References

Kruger D, Marcus AO. Psychological motivation and patient education: a role for continuous glucose monitoring. Diabetes Technol Ther. 2000;2:93. DOI: https://doi.org/10.1089/15209150050214195

Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-41. DOI: https://doi.org/10.1056/NEJMoa1008862

IDF Diabetes Atlas 2025. Diabetes Atlas. 2025. Available from: https://diabetesatlas.org/resources/ idf-diabetes-atlas-2025/. Accessed on 2 March 2025.

Sakthivel S. Access to essential drugs and medicines. In: Commission on Macroeconomics and Health, Financing and delivery of health care services in India. New Delhi: Ministry of Health and Family Welfare, Government of India; 2005:185-210.

Solanki M, Ahir B, Desai C. Cost comparison of different brands of anti-diabetic drugs with Drug Prices Control Order price list. Int J Med Res Health Sci. 2021;10(4):97-104.

Jadhav NB, Bhosale MS, Adhav CV. Cost analysis study of oral antidiabetic drugs available in Indian market. Int J Med Res Health Sci. 2013;2(1):63-9.

Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort-Hasen K, eds. A Textbook of Clinical Pharmacy Practice. 1st ed. Hyderabad: Orient Longman; 2004:72-73.

Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):283. DOI: https://doi.org/10.1371/journal.pmed.0040283

The Drugs (Prices Control) Order, 2013. Available at: https://upload.indiacode.nic.in/showfile?actid=AC_MH_166_1468_00025_00025_1676625785069&type=rule&filename=drug_price_control_order_2013.pdf. Accessed on 02 March 2025.

Dharani Devangi R, Rajesh B, Shashirekha CH, Cost analysis study of commonly used oral hypoglycemic agents available in India- a pharmacoeconomic study. Indian J Pharm Pharmacol. 2017;4(1):22-6.

Shyam S, Mahanthegowda BD. A cost variation analysis of various brands of oral anti-diabetic drugs currently available in Indian pharmaceutical market.Int J Basic Clin Pharmacol. 2020;9:1253-7. DOI: https://doi.org/10.18203/2319-2003.ijbcp20203144

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3. DOI: https://doi.org/10.4103/0250-474X.32139

Chincholkar A, Pentewar G. Cost variation analysis of oral anti-diabetic agents available in drug store of the tertiary care hospital and in Indian market. Int J Basic Clin Pharmacol. 2017;6:1794-8. DOI: https://doi.org/10.18203/2319-2003.ijbcp20172751

Gedam S, Barmaiya N. Cost variation analysis of oral anti-diabetic agents available in Indian market. Int J Basic Clin Pharmacol. 2021;10:694-8. DOI: https://doi.org/10.18203/2319-2003.ijbcp20212080

Gupta KS, Pardeshi ML, Hiray RS. Cost variation analysis of commonly prescribed anti-diabetic drugs available in Indian market: a pharmaco-economic study. Int J Basic Clin Pharmacol. 2022;11:47-51. DOI: https://doi.org/10.18203/2319-2003.ijbcp20214888

Aran KR, Singh S, Gupta GD. Cost variation analysis of oral anti-diabetic drugs currently available in the Indian pharmaceutical market. J Diabetes Metab. 2022;13(8):950.

Sinha P. Pharmacoeconomic comparison of cost variation of oral antidiabetic drugs available in Indian market. Int J Life Sci Biotech Pharma Res. 2024;13(11):341-8.

WHO. Promoting rational use of medicines, 2024. Available at: https://www.who.int/activities/promotingrationaluse-of-medicines. Accessed on 11 April 2025.